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Abstract
Introduction: Primary pulmonary synovial sarcoma is an extremely rare tumor with only few case
reports in the literature.
Case presentation: A healthy 67-year-old woman was admitted for investigation of a pulmonary
mass found on a routine X-ray. She had a history of breast cancer diagnosed and treated 13 years
previously with left mastectomy followed by adjuvant endocrine therapy. No progression of the
disease was reported. Thoracic computer tomography disclosed a soft-tissue mass in the lower
lobe of the left lung arising in the vicinity of the pleura. No abnormal lymph nodes were noted.
Further work-up for metastases was negative. Subsequently, the lower lobe of the left lung was
removed and the diagnosis was a monophasic synovial sarcoma.
Conclusion: The diagnosis of monophasic primary pulmonary synovial sarcoma requires clinical,
imaging and immunohistochemical investigation to exclude alternative primary sources. The
treatment of choice is excision (lobectomy or pneumonectomy), which in most of cases is helpful
for diagnosis. The prognosis is usually poor.
Introduction
Primary synovial sarcoma of the lung is an extremely rare
tumor [1,2] and seems to be strongly related to cigarette
smoking [3]. A definitive diagnosis requires detailed
immunohistochemical staining [4,5], as well as clinical
and imaging investigation to exclude alternative primary
sources.
We describe a case of an asymptomatic, 67-year-old, non
smoking woman with a primary monophasic synovial sar-
coma presenting as a left lower lobe pulmonary mass.
Case presentation
A 67-year-old woman was referred for investigation of a
peripheral opacity in the left lung lower lobe, which was
discovered incidentally on a chest radiograph. Thirteen
years earlier she had undergone a radical left-sided mas-
tectomy for breast cancer, followed by a three-year course
of adjuvant endocrine therapy with tamoxifen. No adju-
vant radiation therapy or chemotherapy was given after
the mastectomy. Until the time of presentation, no evi-
dence of disease recurrence had been found.
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The patient was a housewife, did not smoke or abuse alco-
hol, had no known toxic exposures and denied any family
history of malignancies. She was in good general health
and well nourished. Physical examination was negative
apart from a post-surgical chest scar. The results of blood
tests, standard biochemical tests, urine analysis, c-ANCA,
p-ANCA, tumor markers and arterial blood gas analysis
were normal.
The chest radiograph (Figure 1) revealed a well-demar-
cated, non-cavitating, 3 cm in diameter peripheral opacity
in the left lower lobe, with obtuse angles between the
lesion and the pleura, and no other abnormalities. The
lesion was not apparent on a chest radiograph performed
one year previously. Chest computed tomography (CT),
(Figure 2) confirmed a 3 × 4 cm, oval-shaped, well-delin-
eated peripheral mass in the left lower lobe, abutting the
pleura, homogenous in attenuation and no evidence of
mediastinal or axillary adenopathy. CT of the brain and
abdomen revealed no pathological findings. Pulmonary
function studies were normal. Bronchoalveolar lavage
and bronchial brushing specimens, obtained during bron-
choscopy, were negative for malignancy. The CT-guided
fine needle aspirate from the mass revealed clusters of
neoplastic cells of unclear affiliation, strongly positive on
immunostaining for vimentin and negative for carcino-
embryonic antigen (CEA) and epithelial membrane anti-
gen (EMA).
Finally, a left thoracotomy was performed, revealing a
tumor in the outer part of the left lower lobe, which did
not infiltrate the visceral pleura. Subsequently, a left lower
lobectomy with typical excision of the satellite lymph
nodes was completed. Pathological examination revealed
a well-circumscribed, whitish, soft tumor measuring 2.5 ×
3 × 2 cm. Microscopic examination showed a spindle cell
neoplasm, with slit-like spaces and normal adjacent lung
parenchyma (Figure 3). Immunohistochemical staining
was positive for CD99 and Bcl-2, while staining for EMA,
CK19, CK17, BerEP4, S-100 and thrombomodullin was
negative. The above findings were compatible with a
monophasic spindle cell type synovial sarcoma in the
lung (Figure 4). The lymph nodes showed lesions of reac-
tive lymphadenitis, and the specimens of pleura showed
edema and low-grade inflammation.
Discussion
Synovial sarcoma (SS) is a rare and well-established mes-
enchymal tumor, accounting for approximately 10% of all
soft tissue tumors [6,7]. SS typically presents in adoles-
cents and young adults, most commonly in the soft tissues
of the extremities (especially near large joints), but neck,
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lung, heart, mediastinum and abdominal wall sites have
been reported [6]. The term "synovial" sarcoma was given
because of the synovial differentiation of the tumor that is
believed to originate from multipotential mesenchymal
cells. SS is a highly aggressive tumor affecting males more
often than females, and seems to be strongly related to cig-
arette smoking [3,7].
The generally accepted histological subtypes of synovial
sarcoma are biphasic, monophasic spindle cell or fibrous,
monophasic epithelial and poorly differentiated subtypes
[8]. Among them the monophasic neoplasm subtype
occurs most often in the lung [9]. The biphasic type is eas-
ily diagnosed based on the presence of both epithelial and
spindle cell components. The monophasic type is difficult
to diagnose, because it has a uniform spindle cell pattern;
thus it may be confused with other malignant spindle cell
neoplasms, such as fibrosarcoma, hemangiopericytoma,
leiomyosarcoma and spindle cell carcinoma or carcinosa-
rcoma.
Immunohistochemistry plays a crucial role in the diagno-
sis of SS, especially in monophasic type cases. Most syno-
vial sarcomas show immunoreactivity for cytokeratins
and epithelial membrane antigen (EMA). Furthermore,
30% of them are protein S-100 positive, 60–70% CD 99
positive and 75–100% Bcl-2 positive [10].
Cytogenetics also play an important role since both the
monophasic and the biphasic form are characterised by a
reciprocal chromosomal translocation (x;18) (p
11.2;q11.2). The translocation fuses the SYT gene from
chromosome 18 to either of two homologous genes at
Xp11, SSX1 or SSX2 [11,12]. Despite its high sensitivity,
molecular testing is not required if the diagnosis of syno-
vial sarcoma is certain or probable on the basis of clinical,
histological, and immunohistochemical evaluations
[12,13].
Pulmonary sarcomas are rare accounting for less than
0.5% of lung cancers and most malignant mesenchymal
tumors of the lung are metastases of a primary tumor from
elsewhere [2,6]. Leiomyosarcomas, fibrosarcomas and
hemangiopericytomas are the most common types of pri-
mary pulmonary sarcomas [2]. Primary pulmonary SS are
extremely rare with only few case reports in the literature.
The diagnosis can be established only after clinical and
imaging investigation to exclude alternative primary
sources [1,2,8].
Two thirds of the reported cases primary pulmonary SS
were centrally located and associated with complaints of
postobstructive pneumonia (cough, dyspnea, fever) and
hemoptysis. Peripheral tumors are less common and usu-
ally asymptomatic, but may infiltrate adjacent tissues
(pleura, thoracic wall, and mediastinum) or give rise to
distant metastases (adrenals, brain, and spinal cord) [1,2].
It is noteworthy that in our patient no infiltration of adja-
cent tissues was found.
Sputum examination is rarely helpful and bronchoscopy
is diagnostic in 40–60% of cases. Differential diagnosis
includes bronchogenic carcinoma, different metastatic
lesions, mesothelioma, lymphoma, Wegener's granulo-
matosis, pyogenic abscess, intrapulmonary hematoma,
rheumatoid nodules, histoplasmosis and coccidiomyco-
sis. Lung SS frequently metastasizes to regional lymph
nodes (hilar or mediastinual lymphadenopathy) as well
as to distant sites (adrenals, brain, bone marrow). Owing
to its rarity and the paucity of data regarding its natural
history, there are no guidelines for optimal treatment.
Therefore, current treatment includes surgical resection
(lobectomy or pneumonectomy) followed by adjuvant
radiotherapy or chemotherapy [2,6,14]. Prognosis is
related to the disease stage and is usually poor. In availa-
ble case series and reports, the five-year survival ranges
between 36% and 76% [2]. Our patient underwent a
lobectomy without adjuvant chemotherapy. Five years
and seven months after operation, the patient remains
asymptomatic and without any evidence of disease recur-
rence.
Conclusion
Primary pulmonary synovial sarcoma is an extremely rare
neoplasm. Clinical and imaging investigation is necessary
to exclude alternative primary sources, while a definitive
diagnosis requires detailed immunohistochemical stain-
ing (cytokeratins, vimentin, S100, CD20, CD99, Bcl-2 and
other markers). A balanced chromosomal translocation,
CD99 and Bcl-2 positive spindle-like neoplastic cells (immu- nohistochemical stain, × 100) Figure 4
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t(X;18) (p11.2;q11.2), is found in the majority of synovial
sarcomas resulting in a chimeric transcript, SYT-SSX, the
role of which is so far unclear. Surgical excision with clear
margins and possibly adjuvant chemo-radiotherapy is the
currently accepted treatment.
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